Generating AI analysis...
Revenue
$45.86B
++1.96% YoY
EPS (Basic)
$1.35
++39.18% YoY
Evidence Layer
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Revenue | $45.86B | $44.98B | +1.96% |
Cost of Revenue | $11.94B | $17.39B | -31.33% |
Net Income | $7.62B | $5.49B | +38.87% |
EPS (Basic) | $1.35 | $0.97 | +39.18% |
EPS (Diluted) | $1.34 | $0.96 | +39.58% |
SG&A Expense | $10.46B | $10.2B | +2.55% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Total Assets | $219.48B | $215.02B | +2.07% |
Current Assets | $43.22B | $74.01B | -41.60% |
Total Liabilities | $126.92B | $117.82B | +7.72% |
Current Liabilities | $43.21B | $31.14B | +38.78% |
Stockholders' Equity | $92.29B | $96.93B | -4.80% |
Cash & Equivalents | $1.09B | $3.15B | -65.31% |
Long-Term Debt | $58B | $61.05B | -4.99% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Operating Cash Flow | $6.02B | $3.46B | +74.08% |
Investing Cash Flow | $4.28B | $-21.28B | +120.09% |
Financing Cash Flow | $-12.03B | $20.62B | -158.31% |
D&A | $5.22B | $4.62B | +13.03% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Net Margin | 16.6% | — | — |
ROE | 8.3% | — | — |
ROA | 3.5% | — | — |
Current Ratio | $1 | — | — |
Debt to Equity | $1.375 | — | — |
Other companies in Pharmaceuticals